Tenax Therapeutics/ US88032L6056 /
5/23/2024 3:36:34 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
3.58USD | - | 100 Turnover: 358 |
-Bid Size: - | -Ask Size: - | 3.58 | 3.58 |
GlobeNewswire
5/14
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
4/30
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertens...
GlobeNewswire
4/9
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a...
GlobeNewswire
3/28
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ...
GlobeNewswire
2/29
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT ...
GlobeNewswire
2/20
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimen...
GlobeNewswire
2/8
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimenda...
GlobeNewswire
2/6
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significa...
GlobeNewswire
11/17/2023
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific ...
GlobeNewswire
11/13/2023
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment ...
GlobeNewswire
1/4/2022
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs